Uveitis Disease Market
Uveitis is swelling of the middle layer of the eye, which is called the uvea. It may occur from both infectious and non-infectious causes. It is a group of inflammatory diseases affecting eyes and can cause loss of vision. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn’s disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as Rifabutin and moxifloxacin. Uveitis affects uvea, lens, retina, optic nerve, and vitreous. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis and pan-uveitis based on part of inflammation.
The growth of uveitis market is due to rise in prevalence and complications related to uveitis. In addition, increase in prevalence rates, market players betting heavily on research and development to develop new drugs, an introduction of biologics into the market, fast approval of the drugs are fueling the market growth of uveitis treatment market. According to the Ocular Immunology and Uveitis Foundation, worldwide 2,359,242 people are estimated to have the disorder. Even there are significant advances in research and therapeutics, a prevalence of blindness secondary to uveitis has not been reduced in the past thirty years. However, few factors are restraining the growth of the market such as side effects of the drugs, eye irritation and lack of awareness about eye disorders in undeveloped regions, lack of sufficient healthcare infrastructure is hindering the uveitis treatment system market.
Free sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-uveitis-treatment-market/#ulp-4H8Z4LpNMLEuOnnx
Uveitis treatment market is categorized as-
1. Drug class
• Corticosteroids
• Immunosuppressant
• Monoclonal antibodies
• Antibiotics
• Antivirals
• Antifungal
• Analgesics
2. Disease type
• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis
3. Type of cause
• Infectious Uveitis
• Non-Infectious Uveitis
4. End-users
Hospital Pharmacies, retail pharmacies and others
Free TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-uveitis-treatment-market/#ulp-c654SbFYO64MsOhu
And lastly on the basis of geographical regions global uveitis treatment market segmented into following regions-North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is leading in uveitis treatment market due to various factors such as early approval of drugs compared to other regions, increased R & D investments by market players, and high prevalence of the uveitis is contributing growth of the market. In Europe region due to increased prevalence of diseases such as HIV, multiple sclerosis that are underlying causes of uveitis conditions. Japan, China, and India are expected to play important role in the revenue growth of the Asia-Pacific uveitis treatment market. China and India market growth is due to rapidly developing healthcare infrastructure, increased research and development expenditure and growing awareness about the eye-related diseases. However, manufacturing of eye preparations required aseptic conditions and the manufacturing plant should be GMP certified. Hence the cost related to these preparations is very high that has the direct implication on a cost of the drugs.
Ask Analyst for Full Information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-uveitis-treatment-market/#ulp-14mlyhjMGhVjZqa3
Some of the key players in global uveitis treatment market include AbbVie Inc. (U.S.), Eyegate Pharmaceuticals Inc. (US), Valeant Pharmaceuticals (Bausch + Lomb) (Canada), Novartis AG (Switzerland), Alimera Sciences Inc. (U.S.) and Santen Pharmaceutical Co. Ltd (Japan) to name a few. In 2016, USFDA approved AbbVie’s HUMIRA for the treatment of non-infectious intermediate, posterior and Panuveitis.
Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the Uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious Uveitis. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies. Considering the aforementioned factors global uveitis treatment market is expected to grow at the significant rate.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-uveitis-treatment-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com